TGFB1 and neoplasm: Studies have demonstrated that inhibiting TGF-β, either through small molecules or genetic modifications of CAR T cells to resist TGF-β signalling, can improve CAR T cell persistence, reduce expression of exhaustion markers, enhance cytotoxic activity and improve tumour regression rates [105,106,107,108,109,110].